LCTX — Lineage Cell Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Lineage Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4.34	14.7	8.95	9.5	14.6
Cost of Revenue
Gross Profit	2.92	14	8.27	9.16	14.4
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	53	37.2	33.7	31	51.2
Operating Profit	-48.7	-22.5	-24.7	-21.5	-36.6
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-43.3	-25.8	-23.3	-18.6	-68.6
Provision for Income Taxes
Net Income After Taxes	-43.3	-26.4	-21.5	-18.6	-63.4
Minority Interest
Net Income Before Extraordinary Items
Net Income	-43	-26.3	-21.5	-18.6	-63.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-43	-26.3	-21.5	-18.6	-63.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.265	-0.155	-0.124	-0.093	-0.234